
==== Front
Transl Anim Sci
Transl Anim Sci
tranas
Translational Animal Science
2573-2102
Oxford University Press US

10.1093/tas/txae124
txae124
Microbiome
AcademicSubjects/SCI00960
Oral probiotic administration attenuates postexercise inflammation in horses
Jacobs Robert D Land O Lakes, Purina Animal Nutrition, Gray Summit, MO 63039, USA

Grum Daniel Land O Lakes, Purina Animal Nutrition, Gray Summit, MO 63039, USA

Trible Benjamin Land O Lakes, Purina Animal Nutrition, Gray Summit, MO 63039, USA

Ayala Diana I Land O Lakes, Purina Animal Nutrition, Gray Summit, MO 63039, USA

Karnezos Theodore P Land O Lakes, Purina Animal Nutrition, Gray Summit, MO 63039, USA

Gordon Mary E Land O Lakes, Purina Animal Nutrition, Gray Summit, MO 63039, USA

Corresponding author: rdjacobs@landolakes.com
2024
13 8 2024
13 8 2024
8 txae12422 5 2024
21 8 2024
14 9 2024
© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society of Animal Science.
2024
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Probiotics are commonly incorporated into equine diets to impart health and performance benefits; however, peer-reviewed evidence supporting their efficacy in horses is limited. Interestingly, bacteria from the Bacillus genus are gaining interest for their unique ability to impact metabolic, immune, and inflammatory pathways. The objective of this trial was to evaluate a selection of Bacilli for their role in altering the inflammatory response in horses to exercise. Eighteen horses were utilized in a randomized cross-over trial. Horses were randomly assigned to one of 6 starting treatments including a negative and positive control, and groups that received one of 4 probiotics (Bacillus coagulans GBI-30, 6086, Bacillus subtilis-1, Bacillus subtilis-2, or Bacillus amyloliquefaciens) top dressed to their daily ration at a rate of 8 billion CFU/d mixed into dried whey powder. All horses received a similar base diet of grass hay offered at 2.0% of bodyweight daily along with 4.54 kg of a commercially available textured horse feed. Each 3-wk phase of the trial consisted of a 2-wk dietary acclimation followed by a 1-wk exercise challenge and sample collection. Between phases, horses were offered only their base diet. On the day of exercise, horses were offered their 0700 ration and then subjected to a 2-h standardized exercise test. Blood samples were obtained prior to starting exercise and then again at 0, 2, 4, 6, 8, 24, 48, and 72-h postexercise. Horses in the positive control group were administered 0.23 mg/kg BW flunixin meglumine immediately following the 0-h sampling. Samples were analyzed for serum amyloid A (SAA), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) concentrations. Data were evaluated via ANOVA using the MIXED procedure in SAS 9.4. Exercise-induced inflammation as evidenced by SAA, IL-6, and PGE2 increases postexercise. Horses consuming B. coagulans GBI-30, 6086 had reduced production of SAA, IL-6, and PGE2 compared to all other probiotic-fed groups and the negative control (P < 0.001). The positive control successfully ameliorated the postexercise inflammatory response. These data highlight the potential for B. coagulans GBI-30, 6086 to be incorporated into equine rations as a method to support optimal response to exercise or other inflammation-inducing challenges. Additional research is ongoing to elucidate the methodology by which these results occur.

Supplementation of Bacillus coagulans GBI-30, 6086 reduces exercise-induced inflammation and supports horses through the exercise recovery period.

equine
exercise
inflammation
nutrition
probiotic
==== Body
pmcIntroduction

The use of probiotics to impact animal health and performance has long been established (Schoster et al., 2014). However, the majority of studies in horses have focused on the ability of these additives to impact the hindgut fermentation process (Costa and Weese, 2012; Costa et al., 2012). Recently, researchers have noted the ability of these unique bacteria to impart benefits to host health and performance through a variety of pathways including immune modulation (Guarner and Malagelada, 2003; Jones and Versalovic, 2009), antimicrobial production (Saarela et al., 2000), competitive exclusion of pathogenic bacteria (Collado et al., 2007), and inhibition or inactivation of bacterial toxins (Chen et al., 2006; Allaart et al., 2011). In fact, the most recent definition proposed by the World Health Organization and the Food and Agricultural Organization specifically mentions the ability of these “live microorganisms to...provide a beneficial effect beyond that of their nutritional value” (Kechagia et al., 2013).

There are a variety of commonly utilized microorganisms in equine rations including but not limited to the following genera: Saccharomyces (yeast), Lactobacillus, Bacteroides, Enterococcus, and Streptococcus (Dougal et al., 2013). These have been evaluated due to their relatively high abundance in the colon of the horse and evidence of health-promoting benefit in other species. However, the presence in the colon and impact on overall gastrointestinal health have not been definitively linked. As defined, probiotics must remain alive through manufacturing and storage, a consideration evaluated in previous research (Weese and Martin, 2011). Further, most research on probiotic bacteria has relied upon the assumption that they survive and colonize the equine gastrointestinal tract even after cessation of administration (Kauter et al., 2019), a concept which may limit the application of novel probiotic strains. While it is true that in foals, colonization of certain probiotics has been recorded, the microbiome of mature horses is much less plastic and significantly less likely to allow for the establishment of novel bacterial colonies (Weese et al., 2003).

Bacillus species are widespread in nature and are found across species commonly isolated from the gastrointestinal tract of animals and present in a wide range of environments (Sorokulova et al., 2008). This genus of bacterium is spore-forming and has demonstrated an ability to survive in situations that would otherwise kill other commonly utilized probiotic genera (Nicholson et al., 2000). The most commonly researched strains of Bacillus include Bacillus subtilis, Bacillus coagulans, Bacillus pumilus, and Bacillus licheniforms (Bernardeau et al., 2017). Non-equine studies have identified a variety of health benefits related to the administration of Bacillus probiotics including but not limited to effects on metabolic function (Yang et al., 2015), antioxidant activity (Paik et al., 2005), antimicrobial ability (Jeon et al., 2017; Ayala et al., 2023), and immune modulation (Sarkar et al., 2016). Because of these wide-ranging and varied effects on health and performance, and the increased robustness of these bacteria, these species are well suited, and of interest, to support equine health and performance.

Inflammation is a necessary response by the immune system to injury, disease, infection, or other cellular signals (Schmid-Schonbein, 2006). In horses, inflammation is necessary for optimal immune response to disease as well as exercise recovery and training. However, excess, or prolonged systemic inflammation may result in decreased performance, increased susceptibility to disease, tissue damage, or chronic inflammatory conditions (Vick et al., 2008). Most commonly, inflammation in horses is treated with anti-inflammatory pharmaceuticals or other modalities such as cryotherapy, massage, ultrasound, or laser therapy. Probiotic administration to attenuate inflammation in horses has not yet been widely investigated.

The objective of this trial was to evaluate the effects of 4 unique strains of Bacillus on their ability to alter the inflammatory response of horses undergoing an acute exercise challenge. Based on previous (unpublished) in vitro evaluation of a range of Bacilli using tissue culture, it was hypothesized that one or more of the probiotics would impart an anti-inflammatory effect in vivo, demonstrating a potential unique and specific application of probiotic administration to horses.

Materials and Methods

Animal Care Statement

This study was conducted at the Purina Animal Nutrition Center in Gray Summit, MO. The animal care and handling procedures used in this study along with the sampling protocols were approved by the Institutional Animal Care and Use Committee (Protocol ID: HR367).

Animals and Diet

Eighteen unfit horses of Thoroughbred and American Quarter Horse breeding were utilized for this trial. Table 1 outlines the breakdown of age, breed, sex, body weight (BW), and body condition score of the horses. All horses were housed in a single barn, in individual box stalls (12ʹ × 12ʹ) from approximately 1500–0730 hours daily. Daily turnout was provided by treatment group and gender into approximately 1 acre dry-lots from approximately 0730–1500 hours daily. During turnout and while in stalls, horses had free-choice access to clean water and white salt blocks. Horses were offered 4.54 kg daily of a commercially available textured feed (Purina Omolene 500) split into 2 equal meals at 0700 and 1530 hours daily. Additionally, horses were offered 2.0% BW as grass hay at 1530 hours feeding. Following turnout at 0730 hours daily, horses were offered 2.27 kg/head grass hay fed by turnout group. Feed and hay samples were obtained and evaluated for nutrient profile (Equi Analytical, Ithaca, NY). Table 2 provides a detailed analysis of the diet.

Table 1. Horse enrollment demographics

American quarter horse (n)	10	
Thoroughbred (n)	8	
Mare (n)	5	
Gelding (n)	13	
Age (yr ± SEM)	8.4 ± 1.3	
Starting BCS (± SEM)	5.2 ± 0.5	
Starting BW (kg ± SEM)	511.3 ± 8.5	

Table 2. Nutritional analysis of diets offered to horses

Nutrient	Grass hay	Purina Omolene 500	
DE, Mcal/kg	2.18	3.52	
Crude protein, %	9.50	12.60	
ADF, %	39.00	13.40	
NDF, %	61.70	29.50	
Crude fat, %	2.90	8.60	
Calcium, %	0.33	0.91	
Phosphorus, %	0.20	0.46	
Magnesium, %	0.22	0.32	
Potassium, %	1.63	1.16	
Sodium, %	0.02	0.33	
Iron, mg/kg	85.00	234.00	
Zinc, mg/kg	13.00	227.00	
Copper, mg/kg	6.00	59.00	

Experimental Procedure and Sampling

All horses were on a similar diet prior to enrollment in the trial. Prior to dietary transition a baseline blood sample was obtained via jugular venipuncture and collected in vacutainer tubes (K2 EDTA and SST, Beckton Dickson, NJ) for separation of plasma and serum and analyzed for a complete blood count and for common serum chemistries. All horses were within normal reference ranges for all measured parameters. Horses were transitioned to experimental diets over the course of 2 d. All horses were randomly assigned to one of 6 starting dietary treatment groups. All horses received 15 g of dried whey powder top dressed on to their daily rations at 0700 and 1530 feedings. Horses in the probiotic groups received 4 billion CFU of one of 4 probiotic bacteria (Bacillus coagulans GBI-30, 6086 (Kerry Group, County Kerry, Ireland), Bacillus subtilis-1, Bacillus subtilis-2, or Bacillus amyloliquefaciens) mixed into the dried whey powder. Horses were offered their individual diets for 3-wk periods during which weeks 1–2 were used for dietary acclimation and week 3 was used for exercise challenge and sample collection. Following the final collection on week 3, all horses underwent a 2-d washout and were randomly assigned to a subsequent treatment group. The trial was designed as a randomized cross-over with all horses completing all treatments.

At the start of week 3 of each phase, horses underwent a forced exercise challenge on a circular equine exerciser (Equi-Line Mfg, Burlington, ON). On the morning of the exercise challenge, all horses were offered their 0700 feed approximately 30 min prior to the start of exercise. All horses were exercised for a 2-h period consisting of 4 replications of walk (2.5 m/s) for 3 min, trot (4.5 m/s) for 7 min, and canter (6.2 m/s) for 5 min each in both clockwise and counterclockwise directions. Blood samples were obtained immediately following the cessation of exercise (0-h postexercise) from all horses via jugular venipuncture into vacutainer tubes containing K2 EDTA and blank serum separator tubes for separation of plasma and serum respectively. Additional samples were collected at 2, 4, 6, 8, 24, 48, and 72-h postexercise. Plasma and serum were immediately processed, aliquoted, and stored at −80 °C until analysis. Horses in the positive control group were administered 0.23 mg/kg BW flunixin meglumine (Merck Animal Health, Rahway, NJ) IV immediately following the 0-h postexercise sample collection. Following exercise, all horses were monitored to ensure they returned to resting heart and respiration rates within 60 min postexercise. Following the 8-h postexercise sample collection, all horses were bathed to remove excess sweat buildup.

Inflammatory Marker Analysis

Serum amyloid A (SAA) was evaluated using an automated latex bead-based immunoturbidometric assay (SAA-Vet, Eiken Chemical Co, Japan) at the Cornell Animal Health Diagnostic Center (Ithaca, NY). Prostaglandin E2 (PGE2) was determined in blood samples using a commercially available kit according to manufacturer’s instructions (Enzo Life Science, Farmingdale, NY). The intra- and inter-assay CV for PGE2 analysis were 8.6% and 13.2%, respectively. Interleukin-6 (IL-6) was determined in blood samples using a commercially available kit according to manufacturer’s instructions (R&D Systems, Minneapolis, MN). The intra- and inter-assay CV for IL-6 analysis were 7.2% and 11.8%, respectively.

Statistical Analysis for Inflammatory Markers

Inflammatory marker data were analyzed via ANOVA using the MIXED procedure of SAS 9.4 (SAS Inst. Inc., Cary, NC) with horse as the experimental unit. The model included the fixed effect of timepoint and treatment as well as their interactions. An α of 0.05 or less determined significance with tendencies considered between 0.05 and 0.10. Data are presented as mean ± SEM.

Results

Inflammatory Markers

Utilization of exercise to induce inflammation was successful for all measured variables (Figures 1–3). Serum amyloid A levels increased immediately postexercise, compared to pre-exercise levels, for all treatment groups (P < 0.05). The B. coagulans GBI-30, 6086 group had a reduced SAA level at the 0-h postexercise timepoint compared to all other treatment groups (P < 0.001). At the 2-h postexercise timepoint, the positive control group had similar SAA levels as the B. coagulans GBI-30, 6086 group, and both remained lower compared to all other treatment groups (Bacillus subtilis-1, Bacillus subtilis-2, or Bacillus amyloliquefaciens) until the 24-h postexercise sampling timepoint (P < 0.001). Serum Amyloid A expression in the negative control and all other probiotic-supplemented groups was similar (P > 0.05) to each other through the duration of the sampling period (Figure 1).

Figure 1. Serum amyloid A levels in horses following an exercise challenge.

Interleukin-6 followed a similar expression pattern to that of SAA with a rapid increase at 0-h postexercise (P < 0.001). However, horses supplemented with B. coagulans GBI-30, 6086 had an overall reduced expression of IL-6 compared to all other treatment groups (P < 0.001). Administration of flunixin meglumine in the positive control group provided a quicker reduction in IL-6 compared to all other probiotic treatments except for B. coagulans GBI-30, 6086 (P < 0.001). Horses in the negative control group had a reduced expression of IL-6 compared to the B. subtilis-1, B. amyloliquefaciens, and B. subtilis-2 groups at the 2-h postexercise timepoint (P < 0.05), but levels were similar to the positive control and B. coagulans GBI-30, 6086 groups. All treatment groups returned to baseline levels of IL-6 by the 72-h postexercise sampling timepoint (Figure 3).

Figure 3. Interleukin-6 levels in horses following an exercise challenge.

Prostaglandin E2 levels were similar across all treatment groups at the 0-h postexercise sampling timepoint (P > 0.05). Beginning at 2-h postexercise, the B. coagulans GBI-30, 6086 group had a reduced PGE2 expression compared to all other probiotic-administered groups (P < 0.001). In addition, PGE2 levels returned to baseline quicker when horses were supplemented with B. coagulans GBI-30, 6086 compared to all other probiotic treatments (P < 0.001). Regardless of treatment, PGE2 levels returned to baseline by the 48-h postexercise sampling timepoint (Figure 2). The positive control, flunixin meglumine administration, effectively negated the PGE2 expression following administration (P < 0.001).

Figure 2. Prostaglandin E2 levels in horses following an exercise challenge.

Discussion

Probiotic application to equine diets and rations is common to help support digestive function and immune health. However, the efficacy of these probiotics, and evidence of their benefits to support their widespread application is lacking (Cooke et al., 2021). Research into the role of probiotics in equine nutrition has been limited, focusing on modulation of the equine microbiome (Dougal et al., 2013), direct impact on the fiber fermentation in the hindgut of the horse (Jouany et al., 2008, 2009), and recently the reduction in pathogenic bacteria (Schoster, 2018). Horse owners and veterinarians are routinely looking for ways to support optimal health and performance for horses, and research into probiotic administration to horses for these purposes is necessary (Tanabe et al., 2014).

Bacillus coagulans strains, also referred to as Weizmannia coagulans, and previously, Lactobacillus sporogenes are increasingly used as probiotics in human nutrition. Administration of these bacteria has largely focused on alleviation of irritable bowel syndrome and similar disease states in humans (Hun, 2009; Majeed et al., 2016; Sudha et al., 2018). However, these conditions are largely characterized by increased inflammation and immune dysfunction. Bacillus coagulans GBI-30, 6086 is a unique strain of B. coagulans that has demonstrated significant effects on exercise recovery (Jager et al., 2016) and immune function (Baron, 2009). Both of these benefits are supported by the results of this trial.

This trial utilized an exercise model to induce a systemic inflammatory response in horses. Based on the markers measured in this trial, all horses responded appropriately to exercise and displayed an increased level of systemic inflammation. Serum amyloid A (SAA) is an acute-phase protein synthesized in the hepatocyte of the horse (Eckersall and Bell, 2010), and is considered the only major positive acute-phase protein, meaning that its concentrations are typically undetectable in normal horses, with significant increases in horses undergoing an inflammatory challenge (Crisman et al., 2008). Several studies have evaluated the effects of exercise on SAA levels in horses and have found that regardless of fitness level, an increase in SAA was observed in exercised horses (Cywinska et al., 2010, 2013). The postexercise increase in SAA observed in this trial supports previous findings and highlights the utility of this marker for research trials such as this one. As intended, the use of flunixin meglumine as a positive control in this trial was successful, when evaluating the SAA response to its administration. Horses in the positive control group displayed similar 0-h postexercise SAA concentrations to those in the negative control group but experienced a quick reduction in SAA levels following administration of the anti-inflammatory. Previous research evaluating the use of flunixin meglumine postsurgery supports these findings (Busk et al., 2010). The treatment group that received the Bacillus coagulans GBI-30, 6086 had a reduced SAA response to exercise at all timepoints. This comparative reduction even at the 0-h postexercise timepoint immediately following exercise is likely due to the fact that the horses had been supplemented with Bacillus coagulans GBI-30, 6086 for 14 d prior to the initiation of the exercise trial. This finding is significant in that the application of this probiotic to attenuate the inflammatory response to exercise could prove beneficial to performance horses undergoing long-term or acute training.

It has been reported that in horses, exercise induces a systemic pro-inflammatory response that is highlighted by marked increases in circulating levels of interleukin-6 (Donovan et al., 2007a, 2007b). Similarly to the results for SAA, this trial demonstrates that the ability of B. coagulans GBI-30, 6086 to attenuate IL-6-induced inflammation by both: 1) reducing the initial IL-6 production in response to the exercise challenge and 2) hastening the return to baseline levels compared to other treatment groups and the negative control. The ability of probiotics to modulate immune function is a more recent area of research; it is hypothesized that probiotics impart a significant influence on the gut barrier through direct interaction with enterocytes (Azad et al., 2018). Thus, maintenance of optimal enterocyte health in horses is of utmost importance. Increased intestinal permeability is known to lead to disease as the gut barrier is no longer able to protect against the microbial toxins and pathogens present in the gastrointestinal lumen (Stewart et al., 2017). While the specific mode of action by which the B. coagulans GBI-30, 6086 reduced IL-6 expression was not elucidated in the current study, further research should be conducted to evaluate the effects of B. coagulans GBI-30, 6086 on enterocyte health and intestinal integrity.

Prostaglandin E2 is a physiologically active lipid compound that is known to cause pain in horses through activation of nociceptive neurons (Brunner et al., 2020). The administration of nonsteroidal anti-inflammatory drugs such as flunixin meglumine directly reduces the production of PGE2, thereby acting as an analgesic and anti-inflammatory. Prostaglandin E2 production was increased in response to exercise in this trial, although the lag to peak PGE2, was longer than for IL-6 or SAA. Because of this, the positive control group, which received flunixin meglumine immediately postexercise, had almost no expression of PGE2, highlighting the success of the positive control in mitigating the inflammatory response. Horses who had been consuming B. coagulans GBI-30, 6086 had a reduced expression of PGE2, compared to all other probiotic-supplemented groups and the negative control. The levels of PGE2, in the B. coagulans GBI-30, 6086 supplemented group, were no different than those in the positive control group, indicating that this unique probiotic has an ability to attenuate the inflammatory effects of exercise in a significant manner.

The gastrointestinal tract of the horse is intricately connected to the immune system (Jensen et al., 2010). In fact, approximately 70% of the immune cells are located in the gastrointestinal mucosa and gut associated lymphoid tissue (Ruemmele et al., 2009). Oral probiotics such as B. coagulans GBI-30, 6086 are known to influence both the innate and adaptive immune systems through interaction with the various immune cells located in these tissues (Dominguez-Bello and Blaser, 2008). Through these interactions, the immunomodulatory effects of B. coagulans GBI-30, 6086 are closely intertwined with cytokine expression and production (Ng et al., 2009). Results from this trial support this interaction and demonstrate a novel application for this probiotic in equine diets.

Conclusion

The results of this trial indicate that horses supplemented with 8 billion CFU/d of B. coagulans GBI-30, 6086 displayed a significantly reduced inflammatory response to exercise. The reduction in overall expression of SAA, IL-6, and PGE2 highlights the unique ability of this bacterial strain to reduce the inflammatory load on the horse, thereby promoting a more optimal response to exercise-induced inflammation. Further investigation is warranted to determine the distinct mode of action by which this occurs. These data indicate that inclusion of this specific probiotic bacteria into a daily equine ration may prove beneficial to performance horses or those horses experiencing an increased level of systemic inflammation.

Acknowledgments

Funding in whole for this project was provided by Land O Lakes. We appreciate the support of the leadership of Land O Lakes and Purina Animal Nutrition. Additionally, we would like to express gratitude to the animal care workers who assisted in caring for all horses utilized for this trial in addition to their assistance in sample collection.

Conflict of interest statement

All authors were employed by Land O Lakes (Purina Animal Nutrition) at the time of this study. All appropriate declarations have been made.
==== Refs
Literature Cited

Allaart, J. G., A. J.van Asten, J. C.Vernooij, and A.Grone. 2011. Effect of lactobacillus fermentum on beta2 toxin production by clostridium perfringens. Appl. Environ. Microbiol. 77 :4406–4411. doi:10.1128/AEM.03002-10 21602389
Ayala, D. I., D. S.Grum, N. P.Evans, K. N.Russo, E. A.Kimminau, B. R.Trible, M. M.Lahoti, C. L.Novak, and T. P.Karnezos. 2023. Identification and characterization of the causative agents of Focal Ulcerative Dermatitis in commercial laying hens. Front. Vet. Sci. 10 :1110573. doi:10.3389/fvets.2023.1110573 36846268
Azad, M. A. K., M.Sarker, and D.Wan. 2018. Immunomodulatory effects of probiotics on cytokine profiles. Biomed. Res. Int. 2018 :8063647. doi:10.1155/2018/8063647 30426014
Baron, M. 2009. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad. Med. 121 :114–118. doi:10.3810/pgm.2009.03.1971 19332969
Bernardeau, M., M. J.Lehtinen, S. D.Forssten, and P.Nurminen. 2017. Importance of the gastrointestinal life cycle of Bacillus for probiotic functionality. J. Food Sci. Technol. 54 :2570–2584. doi:10.1007/s13197-017-2688-3 28740315
Brunner, T. J., T. B.Lescun, G. E.Moore, S. E.Grady, A. J.Davern, and S. D.Taylor. 2020. Induction of noninflammatory pain in an experimental foot lameness model in horses. J. Equine Vet. Sci. 87 :102925. doi:10.1016/j.jevs.2020.102925 32172915
Busk, P., S.Jacobsen, and T.Martinussen. 2010. Administration of perioperative penicillin reduces postoperative serum amyloid A response in horses being castrated standing. Vet. Surg. 39 :638–643. doi:10.1111/j.1532-950X.2010.00704.x 20459482
Chen, X., E. G.Kokkotou, N.Mustafa, K. R.Bhaskar, S.Sougioultzis, M.O’Brien, C.Pothoulakis, and C. P.Kelly. 2006. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J. Biol. Chem. 281 :24449–24454. doi:10.1074/jbc.M605200200 16816386
Collado, M. C., L.Grzeskowiak, and S.Salminen. 2007. Probiotic strains and their combination inhibit in vitro adhesion of pathogens to pig intestinal mucosa. Curr. Microbiol. 55 :260–265. doi:10.1007/s00284-007-0144-8 17657533
Cooke, C. G., Z.Gibb, and J. E.Harnett. 2021. The safety, tolerability and efficacy of probiotic bacteria for equine use. J. Equine Vet. Sci. 99 :103407. doi:10.1016/j.jevs.2021.103407 33781424
Costa, M. C., L. G.Arroyo, E.Allen-Vercoe, H. R.Stampfli, P. T.Kim, A.Sturgeon, and J. S.Weese. 2012. Comparison of the fecal microbiota of healthy horses and horses with colitis by high throughput sequencing of the V3-V5 region of the 16S rRNA gene. PLoS One 7 :e41484. doi:10.1371/journal.pone.0041484 22859989
Costa, M. C., and J. S.Weese. 2012. The equine intestinal microbiome. Anim. Health Res. Rev. 13 :121–128. doi:10.1017/S1466252312000035 22626511
Crisman, M. V., W. K.Scarratt, and K. L.Zimmerman. 2008. Blood proteins and inflammation in the horse. Vet. Clin. North Am. Equine Pract. 24 :285–297, vi. doi:10.1016/j.cveq.2008.03.004 18652956
Cywinska, A., R.Gorecka, E.Szarska, L.Witkowski, P.Dziekan, and A.Schollenberger. 2010. Serum amyloid A level as a potential indicator of the status of endurance horses. Equine Vet. J. Suppl 38 :23–27. doi:10.1111/j.2042-3306.2010.00280.x
Cywinska, A., L.Witkowski, E.Szarska, A.Schollenberger, and A.Winnicka. 2013. Serum amyloid A (SAA) concentration after training sessions in Arabian race and endurance horses. BMC Vet. Res. 9 :91. doi:10.1186/1746-6148-9-91 23634727
Dominguez-Bello, M. G., and M. J.Blaser. 2008. Do you have a probiotic in your future? Microbes Infect. 10 :1072–1076. doi:10.1016/j.micinf.2008.07.036 18762263
Donovan, D. C., C. A.Jackson, P. T.Colahan, N.Norton, and D. J.Hurley. 2007a. Exercise-induced alterations in pro-inflammatory cytokines and prostaglandin F2alpha in horses. Vet. Immunol. Immunopathol. 118 :263–269. doi:10.1016/j.vetimm.2007.05.015 17617470
Donovan, D. C., C. A.Jackson, P. T.Colahan, N. N.Norton, J. L.Clapper, J. N.Moore, and D. J.Hurley. 2007b. Assessment of exercise-induced alterations in neutrophil function in horses. Am. J. Vet. Res. 68 :1198–1204. doi:10.2460/ajvr.68.11.1198 17975974
Dougal, K., G. de laFuente, P. A.Harris, S. E.Girdwood, E.Pinloche, and C. J.Newbold. 2013. Identification of a core bacterial community within the large intestine of the horse. PLoS One 8 :e77660. doi:10.1371/journal.pone.0077660 24204908
Eckersall, P. D., and R.Bell. 2010. Acute phase proteins: Biomarkers of infection and inflammation in veterinary medicine. Vet. J. 185 :23–27. doi:10.1016/j.tvjl.2010.04.009 20621712
Guarner, F., and J. R.Malagelada. 2003. Gut flora in health and disease. Lancet 361 :512–519. doi:10.1016/S0140-6736(03)12489-0 12583961
Hun, L. 2009. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad. Med. 121 :119–124. doi:10.3810/pgm.2009.03.1984
Jager, R., K. A.Shields, R. P.Lowery, E. O.De Souza, J. M.Partl, C.Hollmer, M.Purpura, and J. M.Wilson. 2016. Probiotic Bacillus coagulans GBI-30, 6086 reduces exercise-induced muscle damage and increases recovery. PeerJ 4 :e2276. doi:10.7717/peerj.2276 27547577
Jensen, G. S., K. F.Benson, S. G.Carter, and J. R.Endres. 2010. GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol. 11 :15. doi:10.1186/1471-2172-11-15 20331905
Jeon, H. L., N. K.Lee, S. J.Yang, W. S.Kim, and H. D.Paik. 2017. Probiotic characterization of Bacillus subtilis P223 isolated from kimchi. Food Sci. Biotechnol. 26 :1641–1648. doi:10.1007/s10068-017-0148-5 30263701
Jones, S. E., and J.Versalovic. 2009. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 9 :35. doi:10.1186/1471-2180-9-35 19210794
Jouany, J. P., J.Gobert, B.Medina, G.Bertin, and V.Julliand. 2008. Effect of live yeast culture supplementation on apparent digestibility and rate of passage in horses fed a high-fiber or high-starch diet. J. Anim. Sci. 86 :339–347. doi:10.2527/jas.2006-796 17911241
Jouany, J. P., B.Medina, G.Bertin, and V.Julliand. 2009. Effect of live yeast culture supplementation on hindgut microbial communities and their polysaccharidase and glycoside hydrolase activities in horses fed a high-fiber or high-starch diet. J. Anim. Sci. 87 :2844–2852. doi:10.2527/jas.2008-1602 19465499
Kauter, A., L.Epping, T.Semmler, E. M.Antao, D.Kannapin, S. D.Stoeckle, H.Gehlen, A.Lubke-Becker, S.Gunther, L. H.Wieler, et al . 2019. The gut microbiome of horses: current research on equine enteral microbiota and future perspectives. Anim. Microbiome 1 :14. doi:10.1186/s42523-019-0013-3 33499951
Kechagia, M., D.Basoulis, S.Konstantopoulou, D.Dimitriadi, K.Gyftopoulou, N.Skarmoutsou, and E. M.Fakiri. 2013. Health benefits of probiotics: a review. ISRN Nutr. 2013 :481651. doi:10.5402/2013/481651 24959545
Majeed, M., K.Nagabhushanam, S.Natarajan, A.Sivakumar, F.Ali, A.Pande, S.Majeed, and S. K.Karri. 2016. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr. J. 15 :21. doi:10.1186/s12937-016-0140-6 26922379
Ng, S. C., A. L.Hart, M. A.Kamm, A. J.Stagg, and S. C.Knight. 2009. Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis. 15 :300–310. doi:10.1002/ibd.20602 18626975
Nicholson, W. L., N.Munakata, G.Horneck, H. J.Melosh, and P.Setlow. 2000. Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments. Microbiol. Mol. Biol. Rev. 64 :548–572. doi:10.1128/MMBR.64.3.548-572.2000 10974126
Paik, H. D., J. S.Park, and E.Park. 2005. Effects of Bacillus polyfermenticus SCD on lipid and antioxidant metabolisms in rats fed a high-fat and high-cholesterol diet. Biol. Pharm. Bull. 28 :1270–1274. doi:10.1248/bpb.28.1270 15997112
Ruemmele, F. M., D.Bier, P.Marteau, G.Rechkemmer, R.Bourdet-Sicard, W. A.Walker, and O.Goulet. 2009. Clinical evidence for immunomodulatory effects of probiotic bacteria. J. Pediatr. Gastroenterol. Nutr. 48 :126–141. doi:10.1097/MPG.0b013e31817d80ca 19179874
Saarela, M., G.Mogensen, R.Fonden, J.Matto, and T.Mattila-Sandholm. 2000. Probiotic bacteria: safety, functional and technological properties. J. Biotechnol. 84 :197–215. doi:10.1016/s0168-1656(00)00375-8 11164262
Sarkar, A., S. M.Lehto, S.Harty, T. G.Dinan, J. F.Cryan, and P. W. J.Burnet. 2016. Psychobiotics and the manipulation of bacteria-gut-brain signals. Trends Neurosci. 39 :763–781. doi:10.1016/j.tins.2016.09.002 27793434
Schmid-Schonbein, G. W. 2006. Analysis of inflammation. Annu. Rev. Biomed. Eng. 8 :93–131. doi:10.1146/annurev.bioeng.8.061505.095708 16834553
Schoster, A. 2018. Probiotic use in equine gastrointestinal disease. Vet. Clin. North Am. Equine Pract. 34 :13–24. doi:10.1016/j.cveq.2017.11.004 29402478
Schoster, A., J. S.Weese, and L.Guardabassi. 2014. Probiotic use in horses – what is the evidence for their clinical efficacy? J. Vet. Intern. Med. 28 :1640–1652. doi:10.1111/jvim.12451 25231539
Sorokulova, I. B., I. V.Pinchuk, M.Denayrolles, I. G.Osipova, J. M.Huang, S. M.Cutting, and M. C.Urdaci. 2008. The safety of two Bacillus probiotic strains for human use. Dig. Dis. Sci. 53 :954–963. doi:10.1007/s10620-007-9959-1 17934835
Stewart, A. S., S.Pratt-Phillips, and L. M.Gonzalez. 2017. Alterations in intestinal permeability: the role of the “leaky gut” in health and disease. J. Equine Vet. Sci. 52 :10–22. doi:10.1016/j.jevs.2017.02.009 31000910
Sudha, M. R., N.Jayanthi, M.Aasin, R. D.Dhanashri, and T.Anirudh. 2018. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef. Microbes 9 :563–572. doi:10.3920/BM2017.0129 29695183
Tanabe, S., T.Suzuki, Y.Wasano, F.Nakajima, H.Kawasaki, T.Tsuda, N.Nagamine, T.Tsurumachi, K.Sugaya, H.Akita, et al . 2014. Anti-inflammatory and intestinal barrier-protective activities of commensal lactobacilli and bifidobacteria in thoroughbreds: role of probiotics in diarrhea prevention in neonatal thoroughbreds. J. Equine Sci. 25 :37–43. doi:10.1294/jes.25.37 25013357
Vick, M. M., B. A.Murphy, D. R.Sessions, S. E.Reedy, E. L.Kennedy, D. W.Horohov, R. F.Cook, and B. P.Fitzgerald. 2008. Effects of systemic inflammation on insulin sensitivity in horses and inflammatory cytokine expression in adipose tissue. Am. J. Vet. Res. 69 :130–139. doi:10.2460/ajvr.69.1.130 18167098
Weese, J. S., M. E.Anderson, A.Lowe, and G. J.Monteith. 2003. Preliminary investigation of the probiotic potential of Lactobacillus rhamnosus strain GG in horses: fecal recovery following oral administration and safety. Can. Vet. J. 44 :299–302.12715981
Weese, J. S., and H.Martin. 2011. Assessment of commercial probiotic bacterial contents and label accuracy. Can. Vet. J. 52 :43–46.21461205
Yang, H. J., D. Y.Kwon, H. J.Kim, M. J.Kim, D. Y.Jung, H. J.Kang, D. S.Kim, S.Kang, N. R.Moon, B. K.Shin, et al . 2015. Fermenting soybeans with Bacillus licheniformis potentiates their capacity to improve cognitive function and glucose homeostasis in diabetic rats with experimental Alzheimer’s type dementia. Eur. J. Nutr. 54 :77–88. doi:10.1007/s00394-014-0687-y 24700374
